A novel approach to inoperable or recurrent rectal cancer by chemoembolization: A new arrow in our quiver?

• Published in: Oncotarget Vol. 7; no. 29; pp. 45275 - 45282
• Main Authors: Bini, Roberto, Comelli, Simone, Leli, Renzo, Vaudano, Giacomo Paolo, Savio, Daniele, Viora, Tiziana, Addeo, Alfredo
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 19-07-2016
• Subjects: Aged; Aged, 80 and over; Chemoembolization, Therapeutic; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - therapy; Prospective Studies; Rectal Neoplasms - mortality; Rectal Neoplasms - therapy; Research Paper; chemoembolization; debiri; cancer recurrence; rectal cancer
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.9940

Assess the feasibility, safety and efficacy of TACE with irinotecan loaded micro particles (debiri) for the treatment of locally advanced rectal cancer patients.
We assessed the Edmonton Symptom Assessment System (ESAS). The tool is designed to assess nine common symptoms in cancer patients: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing and shortness of breath. The ESAS score was 7 in 10/12 (83%) patients before treatment and 6 in 2/12 (16.5%) patients. After treatment in 6/12 (50%) patients the score dropped to 3; 3/12 (33%) reported 4, 1/12 (8%) reported 2. All patients experienced local control disease with a degree of citoreduction; in 4 cases (33%) we observed outstanding responses with a dramatic reduction in the tumors size which led us to surgical radical resections.
We run a prospective mono-institutional study where we recruited, 12 non- consecutive patients with histology confirmation of rectal cancer, inoperable and not treatable due to severe comorbidities, or pelvic recurrence/progression after curative treatment, chemotherapy, radiotherapy and/or surgery. Their performance status (PS) ECOG was 2-3 . Twelve patients (10 male and 2 female) with a median age 71 (range 56-89) were recruited in the study.
The study has met the primary endpoint and showed encouraging activity. Debiri could be a possible option for locally advanced/inoperable or recurred rectal cancer patients. Further trials are warranted to validate this methodic in early stages.